Silence Therapeutics plc (SLN) shareholders
Close on Nov 17, 2026Market cap $935.48MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Richard Ian Griffiths Joint filing with Ora Capital Limited (13.60%) | 34,543,302 | 24.40% | 13D (active) amendment | Jun 25, 2025 |
| Richard Griffiths | 14,391,498 | 7.97% | 13D (active) amendment | Aug 12, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (7.10%) | 13,180,206 | 7.10% | 13G (passive) | Sep 30, 2026 |
| Raymond Debbane Joint filing with Invus Public Equities, L.P. (6.10%), Invus Public Equities Advisors, LLC (6.10%) and 2 more | 9,934,314 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Tetragon Financial Management LP Joint filing with Tetragon Financial Group Limited (5.30%), Patrick G. G. Dear (5.30%) and 1 more | 9,878,565 | 5.30% | 13G (passive) amendment | Oct 5, 2026 |
| Tetragon Financial Group Limited Joint filing with Tetragon Financial Management LP (5.20%), Patrick G. G. Dear (5.20%) and 1 more | 9,708,153 | 5.20% | 13G (passive) | Oct 5, 2026 |
| Invus Public Equities Advisors, LLC Joint filing with Invus Public Equities, L.P. (7.80%), Artal International S.C.A (7.80%) and 5 more | 9,000,000 | 7.80% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SLN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Siren, L.L.C. | 3,311,438 | – | $36.36M | +400,000 | 0.74% |
| TCG Crossover Management, LLC | 3,033,560 | – | $33.31M | – | 0.80% |
| Nantahala Capital Management, LLC | 2,693,462 | – | $29.57M | +546,731 | 0.49% |
| Redmile Group, LLC | 2,164,777 | – | $23.77M | – | 1.60% |
| Citadel Advisors LLC | 1,329,625 | – | $14.60M | +94,818 | 0.00% |
| Nextech Invest, Ltd. | 952,400 | – | $10.46M | – | 0.50% |
| Millennium Management LLC | 909,279 | – | $9.98M | −164,912 | 0.00% |
| Ikarian Capital, LLC | 830,784 | – | $1.83M | −35,000 | 0.20% |
| TFG Asset Management GP Ltd | 764,256 | – | $8.39M | +134,095 | 1.32% |
| Soleus Capital Management, L.P. | 630,000 | – | $6.92M | New | 0.24% |
| Balyasny Asset Management L.P. | 610,980 | – | $6.71M | New | 0.01% |
| 5AM Venture Management, LLC | 476,200 | – | $5.23M | – | 1.82% |
| Great Point Partners LLC | 450,000 | – | $4.94M | −570,489 | 0.93% |
| Morgan Stanley | 403,172 | – | $4.43M | +337,686 | 0.00% |
| Ameriprise Financial Inc | 370,052 | – | $4.06M | New | 0.00% |
| Jane Street Group, LLC | 369,151 | – | $4.05M | +268,224 | 0.00% |
| ADAR1 Capital Management, LLC | 338,373 | – | $3.72M | +166,216 | 0.17% |
| SummitTX Capital, L.P. | 326,648 | – | $3.59M | New | 0.09% |
| Schonfeld Strategic Advisors LLC | 269,348 | – | $2.96M | New | 0.01% |
| UBS Group AG | 243,152 | – | $2.67M | −3,785 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 24M | 20 / 22 | 18 / 4 | 5M | 2M |
| Q1 2026 | 56 | 20M | 6 / 24 | 11 / 7 | 4M | 2M |
| Q4 2025 | 58 | 18M | 14 / 15 | 17 / 10 | 3M | 5M |
| Q3 2025 | 54 | 20M | 6 / 15 | 16 / 7 | 0M | 0M |
| Q2 2025 | 55 | 20M | 9 / 13 | 18 / 13 | 1M | 3M |
| Q1 2025 | 59 | 22M | 6 / 18 | 25 / 11 | 2M | 4M |
| Q4 2024 | 65 | 25M | 16 / 24 | 13 / 20 | 5M | 8M |
| Q3 2024 | 69 | 28M | 13 / 24 | 16 / 15 | 8M | 9M |
| Q2 2024 | 71 | 29M | 12 / 23 | 20 / 5 | 5M | 4M |
| Q1 2024 | 64 | 28M | 32 / 17 | 11 / 2 | 13M | 6M |
| Q4 2023 | 34 | 21M | 8 / 9 | 6 / 2 | 2M | 1M |
| Q3 2023 | 28 | 20M | 4 / 4 | 7 / 5 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
9 funds held SLN in Q2 2026, 82% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SLN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Advisor Biotechnology Fund | 482,088 | – | $5.06M | 0.23% | Jul 31, 2026 |
| iShares Biotechnology ETF | 185,777 | – | $2.04M | 0.02% | Jun 30, 2026 |
| Alger Small Cap Growth Fund | 105,679 | – | $1.11M | 0.54% | Jul 31, 2026 |
| Alger Small Cap Growth Institutional Fund | 41,292 | – | $433.15K | 0.54% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 29,538 | – | $203.81K | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 9,532 | – | $104.66K | 0.01% | Jun 30, 2026 |
| ActivePassive International Equity ETF | 8,695 | – | $60.00K | 0.01% | May 31, 2026 |
| Steward Values Enhanced International Fund | 5,800 | – | $60.84K | 0.02% | Jul 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 2,476 | – | $17.08K | 0.03% | May 31, 2026 |
| ProShares Ultra Nasdaq Biotechnology | 1,736 | – | $11.98K | 0.02% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 1,000 | – | $10.98K | 0.00% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 24 | – | $264 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Rhonda Lynette Hellums | Chief Financial Officer, Director | 1,500 | Jan 6, 2026 |
| Iain Ross | Interim PEO, Director | 39,942 | Dec 22, 2025 |
| Craig A. Tooman | President and CEO, Director | 33,486 | Jan 6, 2025 |
| Steven J. Romano | EVP and Chief R&D Officer | 12,993 | Jan 6, 2026 |
| James Ede-Golightly | Director | 15,000 | Jan 6, 2026 |
| Timothy McInerney | Director | – | Jan 6, 2026 |
| David Lemus | Director | 7,527 | Jan 6, 2026 |
| Michael H. Davidson | Director | 12,993 | Jan 6, 2025 |
| Richard Ian Griffiths | 10% owner | – | Aug 13, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Silence Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,509 shares on Sep 2, 2026 over the last 90 days.
See a number that looks wrong?